Table 4:

Baseline ctDNA results for samples with Relevant Co-occurring Alterations

Patient Number	SNV/InDel	CNV	Dose and Cohort	Time to Progression (weeks)
1	CDK12 K480		100 mg - C	19
	CDK12 L867P
	AR L702H
2		AR amplification	200 mg - C	30
		RB1 homozygous del
3	PIK3CA N345K	BRCA2 LOH deletion	200 mg - N	13
	ATM M2405V	RB1 deletion
	AR L702H	AR amplification
4		AR amplification	200 mg - N	31
		BRCA2 homozygous del
		RB1 LOH deletion
5	PIK3CA N345K	PIK3CA amplification	100 mg - N	15
		AR amplification
		RB1 homozygous del
6	AR W742C	RB1 homozygous del	100 mg - N	32
	EGFR D837N	EGFR amplification
7	AR F877L	ATM LOH deletion	100 mg - N	21
	PIK3CA H1047R	BRCA2 LOH deletion
		RB1 deletion
8	BRAF K601E		300 mg - N	38
	AR T878A
	BRCA2 H1003fs (g)
	BRCA2 Q2859fs
	RB1 L572fs
9		BRCA2 deletion	200 mg - C	12
		RB1 LOH deletion
		PIK3CA amplification
		AR amplification
10	BRCA2 c682–1G>A		100 mg - C	49
	BRCA2 K2849fs (g)
11	PIK3CA H1047R	AR amplification	100 mg - C	18

Legend: ctDNA = circulating tumor DNA, C = prior chemotherapy, N = chemotherapy naïve, CNV=copy number variant, SNV= single nucleotide variant, InDel= insertion/deletion variant, LOH = loss of heterozygosity, del = deletion, fs = frameshift, (g) = germline